These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30262033)

  • 1. T Lymphocyte-Based Cancer Immunotherapeutics.
    Borrie AE; Maleki Vareki S
    Int Rev Cell Mol Biol; 2018; 341():201-276. PubMed ID: 30262033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches in cancer immunotherapy.
    Subramaniam DS; Liu SV; Giaccone G
    Discov Med; 2016 Apr; 21(116):267-74. PubMed ID: 27232512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy a New Hope for Cancer Treatment: A Review.
    Nouri Rouzbahani F; Shirkhoda M; Memari F; Dana H; Mahmoodi Chalbatani G; Mahmoodzadeh H; Samarghandi N; Gharagozlou E; Mohammadi Hadloo MH; Maleki AR; Sadeghian E; Nia E; Nia N; Hadjilooei F; Rezaeian O; Meghdadi S; Miri S; Jafari F; Rayzan E; Marmari V
    Pak J Biol Sci; 2018; 21(3):135-150. PubMed ID: 30187723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint modulation: rational design of combination strategies.
    Zamarin D; Postow MA
    Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
    Kyi C; Postow MA
    Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
    Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
    Joshi M; Pal SK; Drabick JJ
    Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of cancer immunotherapy toxicity.
    Kennedy LB; Salama AKS
    CA Cancer J Clin; 2020 Mar; 70(2):86-104. PubMed ID: 31944278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
    Khalil DN; Smith EL; Brentjens RJ; Wolchok JD
    Nat Rev Clin Oncol; 2016 May; 13(5):273-90. PubMed ID: 26977780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
    Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
    Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer immunotherapy: moving forward with peptide T cell vaccines.
    Kumai T; Fan A; Harabuchi Y; Celis E
    Curr Opin Immunol; 2017 Aug; 47():57-63. PubMed ID: 28734176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation approaches for tumor vaccination.
    Patel A; Kaufman HL; Disis ML
    Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?
    Gerber HP; Sapra P; Loganzo F; May C
    Biochem Pharmacol; 2016 Feb; 102():1-6. PubMed ID: 26686577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and future prospects of peptide-based cancer vaccines.
    Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T
    Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapies and Combination Strategies for Immuno-Oncology.
    Barbari C; Fontaine T; Parajuli P; Lamichhane N; Jakubski S; Lamichhane P; Deshmukh RR
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32679922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.